|
BOLD wishes to acknowledge the contributions of Georg Harnoncourt of the ndd
Corporation and Paul Enright for their assistance with spirometry training and
quality control during the study.
The BOLD initiative has been funded in part by unrestricted educational grants
to the Operations Center (www.boldcopd.org)
from ALTANA, Aventis, AstraZeneca, Boehringer-Ingelheim, Chiesi,
GlaxoSmithKline, Merck, Novartis, Pfizer, Schering-Plough, Sepracor, and
University of Kentucky.
Additional local support for BOLD clinical sites was provided by: Boehringer
Ingelheim China. (GuangZhou, China ); Turkish Thoracic
Society, Boehringer-Ingelheim, and Pfizer (Adana, Turkey
); Altana, Astra-Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Sharpe
& Dohme, Novartis, Salzburger Gebietskrankenkasse and Salzburg Local
Government (Salzburg, Austria ); Research for
International Tobacco Control, the International Development Research Centre,
the South African Medical Research Council, the South African Thoracic Society
GlaxoSmithKline Pulmonary Research Fellowship, and the University of Cape Town
Lung Institute (Cape Town, South Africa ); and
Landspitali University Hospital Research Fund, GlaxoSmithKline Iceland, and
AstraZeneca Iceland (Reykjavik, Iceland );
GlaxoSmithKline Pharmaceuticals, Polpharma, Ivax Pharma Poland, AstraZeneca
Pharma Poland, ZF Altana Pharma, Pliva Kraków, Adamed, Novartis Poland, Linde
Gaz Polska, Lek Polska, Tarchominskie Zaklady Farmaceutyczne Polfa, Starostwo
Proszowice, Skanska, Zasada, Agencja Mienia Wojskowego w Krakowie,
Telekomunikacja Polska, Biernacki, Biogran, Amplus Bucki, Skrzydlewski, Sotwin,
and Agroplon (Cracow, Poland); Boehringer-Ingelheim,
and Pfizer Germany (Hannover, Germany ); the Norwegian
Ministry of Health’s Foundation for Clinical Research, and Haukeland University
Hospital’s Medical Research Foundation for Thoracic Medicine (Bergen, Norway);
AstraZeneca, Boehringer-Ingelheim, Pfizer, and GlaxoSmithKline (Vancouver,
Canada); Marty Driesler Cancer Project (Lexington,
Kentucky, USA); Altana, Boehringer Ingelheim (Phil),
GlaxoSmithKline, Pfizer, Philippine College of Chest Physicians, Philippine
College of Physicians, and United Laboratories (Phil) (Manila, Philippines);
Air Liquide Healthcare P/L, AstraZeneca P/L, Boehringer Ingelheim P/L,
GlaxoSmithKline Australia P/L, Pfizer Australia P/L (Sydney, Australia);
Swedish Heart Lung Foundation, Swedish Association Against Heart and Lung
Diseases, Bror Hjerstedt Foundation, GlaxoSmithKline Sweden (Uppsala, Sweden);
Department of Health Policy Research Programme (London, United Kingdom).
|